Kilitch Drugs (India) Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 299.72 million compared to INR 344.31 million a year ago. Revenue was INR 306.59 million compared to INR 357.4 million a year ago. Net income was INR 23.71 million compared to INR 11.25 million a year ago. Basic earnings per share from continuing operations was INR 1.52 compared to INR 0.72 a year ago. Diluted earnings per share from continuing operations was INR 1.52 compared to INR 0.72 a year ago.
For the nine months, sales was INR 941.22 million compared to INR 776.27 million a year ago. Revenue was INR 960.2 million compared to INR 801.58 million a year ago. Net income was INR 68.85 million compared to INR 44.69 million a year ago. Basic earnings per share from continuing operations was INR 4.42 compared to INR 2.87 a year ago. Diluted earnings per share from continuing operations was INR 4.42 compared to INR 2.87 a year ago.